Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models

View ORCID ProfileAshlee D. Brunaugh, Hyojong Seo, View ORCID ProfileZachary Warnken, Li Ding, Sang Heui Seo, View ORCID ProfileHugh D.C. Smyth
doi: https://doi.org/10.1101/2020.09.24.310490
Ashlee D. Brunaugh
1Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Ave, Austin TX, 78712
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashlee D. Brunaugh
Hyojong Seo
1Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Ave, Austin TX, 78712
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary Warnken
1Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Ave, Austin TX, 78712
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zachary Warnken
Li Ding
1Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Ave, Austin TX, 78712
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sang Heui Seo
2Laboratory of Influenza Research, College of Veterinary Medicine, Chungnam National University, 99 Dae-Hak Ro, Yoseong Gu, Dajeon, Korea, 34134
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugh D.C. Smyth
1Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Ave, Austin TX, 78712
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hugh D.C. Smyth
  • For correspondence: hugh.smyth@austin.utexas.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT

Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, the oral formulation produces systemic drug levels that are too low to inhibit SARS-CoV-2. As an alternative, direct delivery of NIC to the respiratory tract as an aerosol could target the primary site of for SARS-CoV-2 acquisition and spread. We have developed a niclosamide powder suitable for delivery via dry powder inhaler, nebulizer, and nasal spray through the incorporation of human lysozyme (hLYS) as a carrier molecule. This novel formulation exhibits potent in vitro and in vivo activity against MERS-CoV and SARS-CoV-2 and protects against methicillin-resistance staphylococcus aureus pneumonia and inflammatory lung damage. The suitability of the formulation for all stages of the disease and low-cost development approach will ensure wide-spread utilization.

Competing Interest Statement

An author (HDCS) of this paper consults for and has equity ownership in Respira Therapeutics, Nob Hill Therapeutics, Via Therapeutics, LLC and CloXero Therapeutics, Inc on inhaled product development. An author of this paper (ADB) is an employee of Via Therapeutics, LLC and has equity ownership in CloXero Therapeutics, Inc. An author of this paper (ZW) is an employee of Via Therapeutics, LLC. The terms of this arrangement have been reviewed and approved by the University of Texas at Austin in accordance with its policy on objectivity in research.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 24, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models
Ashlee D. Brunaugh, Hyojong Seo, Zachary Warnken, Li Ding, Sang Heui Seo, Hugh D.C. Smyth
bioRxiv 2020.09.24.310490; doi: https://doi.org/10.1101/2020.09.24.310490
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models
Ashlee D. Brunaugh, Hyojong Seo, Zachary Warnken, Li Ding, Sang Heui Seo, Hugh D.C. Smyth
bioRxiv 2020.09.24.310490; doi: https://doi.org/10.1101/2020.09.24.310490

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4231)
  • Biochemistry (9124)
  • Bioengineering (6774)
  • Bioinformatics (23975)
  • Biophysics (12114)
  • Cancer Biology (9515)
  • Cell Biology (13772)
  • Clinical Trials (138)
  • Developmental Biology (7623)
  • Ecology (11681)
  • Epidemiology (2066)
  • Evolutionary Biology (15497)
  • Genetics (10634)
  • Genomics (14314)
  • Immunology (9475)
  • Microbiology (22825)
  • Molecular Biology (9087)
  • Neuroscience (48935)
  • Paleontology (355)
  • Pathology (1480)
  • Pharmacology and Toxicology (2566)
  • Physiology (3844)
  • Plant Biology (8322)
  • Scientific Communication and Education (1470)
  • Synthetic Biology (2295)
  • Systems Biology (6184)
  • Zoology (1300)